Why Is CHARLES RIV LABORATO (CRL) Stock Moving Today?
CHARLES RIV LABORATO (CRL) is drawing unusual attention today. Our newswire has captured 10 stories on CRL across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Charles River Laboratories International Inc. shares rose 5.59% to $292.82 on Tuesday, driven by the release of a new strategic vision at the company’s 2026 Investor Day and broader industry forecasts for growth in contract research and drug safety markets. The stock opened at $278.01 and reached an intraday high of $294.24 before settling near the session’s top. The move follows a wave of market research reports highlighting expanding opportunities in AI-enabled clinical trials and outsourcing services.
What Happened
The company outlined a refreshed strategic vision at its 2026 Investor Day, emphasizing profitable growth and long-term value creation. This event coincided with the release of a slide deck detailing its outlook and operational roadmap. Separately, multiple market research reports from the past 36 hours projected significant growth in the contract research organization and drug safety markets, with Charles River Laboratories named among key industry players. These reports highlighted AI-driven innovations, global patient recruitment, and real-world evidence as key growth drivers. The SEC also filed an 8-K on behalf of CRL, disclosing Regulation FD information and related financial statements.
What The Data Shows
The stock’s intraday session showed strong volatility, with a high of $294.24 at 9:45 AM ET and a low of $276.70 shortly after the open. Volume remained subdued at 0.0M shares, significantly below its 3-month daily average. Despite the rally, CRL remains unprofitable with a trailing twelve-month EPS of -4.88 and a net margin of -6.0%. The stock is currently trading near its 52-week high of $303.31. The 52-week tape also showed one fresh 52-week low and 12 fresh 52-week highs on September 24, suggesting a mixed but active market environment.
What To Watch
The company is expected to report FY26 revenue and non-GAAP earnings in the coming months. Investors should monitor the breadth of coverage and any follow-up analyst commentary, particularly from Evercore ISI Group, which recently raised its price target to $320.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CRL by the numbers
The headlines behind the move
Charles River rises on Investor Day on promising 2026 outlook
Charles River Laboratories (CRL) stock rises as the company targets the high end of 2026 guidance and unveils 2030 outlook. Read more here.
Why is Charles River Laboratories stock surging today?
Why is Charles River Laboratories stock surging today?
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day - Slideshow
2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.
Contract Research Organization Services Market Forecasts Growth from $107.03B (2025) to $180.56B by 2030, Profiling IQVIA, Charles River, Syneos Health & WuXi AppTec
Opportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence...
Drug Safety Market Forecasts Growth from $7.12B (2026) to $10.21B by 2032, Profiling IQVIA, ICON, Charles River, Oracle & Parexel
Opportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in...
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) files 8-K
Filed: 2026-09-24 AccNo: 0001100682-26-000142 Size: 1 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
Secure the Global Drug Discovery Services Report: Capitalize on AI-driven outsourcing and benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Syngene before rivals capture the next revenue wave
Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support...
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors
Frequently asked questions
Why is CRL stock moving today?
CHARLES RIV LABORATO (CRL) is drawing unusual attention today. Our newswire has captured 10 stories on CRL across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100). The most recent driver: "Charles River Laboratories International Inc. stock outperforms competitors on strong trading day" (MarketWatch).
Is CRL a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CRL coverage reads 56/100 over 10 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is TWST up today (+16.11%)
- Why is GRAL up today (+15.38%)
- Why is SECZ up today (+15.11%)
- Why is CDNA up today (+13.00%)
- Why is ACAD down today (-12.78%)
- Why is WRBY up today (+12.51%)
More on CRL: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier CRL move explainers: 2026-09-24